Highlights:
• First progression-free survival (“PFS”) data expected from late-stage Phase IIb metastatic breast cancer study, AIPAC, in March 2020
• More mature data expected from TACTI-002 in February 2020
• Sufficiently funded to deliver key upcoming catalysts
For more information, please download the attached PDF
Download this document
